Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Algeta
Algeta
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Pharmaceutical
Thomas Ramdahl appointed as Managing Director of Algeta
Bayer has completed the acquisition of the Norwegian developer of cancer drugs
Research & Development
Algeta appoints Chief Scientific Officer
Dr Andreas Menrad takes responsibility for the Norwegian company\'s research strategy
Manufacturing
Algeta opens commercial production facility for Xofigo in Norway
The plant for the manufacture of the cancer treatment is based at the Institute for Energy Technology (IFE) in Norway
Manufacturing
Cobra Biologics and Algeta sign monoclonal antibody manufacturing agreement
Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies
Norwegian cancer therapeutics developer appoints president
Jeffrey Albers takes up the role at Algeta US
Regulatory
Anticancer agent – radium-223 chloride
Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development
Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227
Norwegian firm to create pipeline of cancer-destroying drugs
Subscribe now